Comparison Study of the Bio-Plex and Meso Scale Multiplexed SARS-CoV-2 Serology Assays Reveals Evidence of Diminished Host Antibody Responses to SARS-CoV-2 after Monoclonal Antibody Treatment

By sjmartinez • August 22, 2024

Parikh UM, Heaps AL, Moisi D, Gordon KC, Mellors JW, Choudhary MC, Deo R, Moser C, Klekotka P, Landay AL, Currier JS, Eron JJ, Chew KW, Smith DM, Li JZ, Sieg SF; Team ACTIV-2/A5401 Study. Comparison Study of the Bio-Plex and Meso Scale Multiplexed SARS-CoV-2 Serology Assays Reveals Evidence of Diminished Host Antibody Responses to SARS-CoV-2 after Monoclonal Antibody Treatment. Pathog Immun. 2024 Aug 15;9(2):58-78. doi: 10.20411/pai.v9i2.715. PMID: 39165724; PMCID: PMC11335343.

Tags: bamlanivimab, Bio-Plex, Covid, covid-19, Infectious Diseases, Meso Scale Discovery, Monoclonal antibodies, Publications, SARS-CoV-2

Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis

Gebremariam T, Gu Y, Patterson H, Youssef E, Alkhazraji S, Elsayed T, Wiederhold NP, Ibrahim AS. Efficacy assessments of SF001, a next-generation polyene antifungal, in[...]

Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia

Dao KT, D'Assumpcao C, Sharma R, Singh C, Kuran R, Heidari A. Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia. Cureus. 2025 Feb 24;17(2):e79588.[...]

Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial

Giganti MJ, Chew KW, Moser C, Eron JJ, Pinilla M, Li JZ, Ritz J, Javan AC, Wohl DA, Daar ES, Currier JS, Smith DM, Hughes[...]